Drug recall · February 23, 2022
Moxifloxacin Ophthalmic Solution recall
Why: Failed Impurities/Degradation Specifications
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Moxifloxacin Ophthalmic Solution, USP 0.5% w/v, 3 mL bottle, Sterile, Rx Only, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ 08520, Made in India, NDC 65862-840-03
- Lots / codes
Lot#: CMF210001, CMF210003, CMF210004, Exp 6/2023
- Quantity
- 115776 bottles
- Company
- Aurobindo Pharma USA Inc., East Windsor, NJ
- Distribution
- USA Nationwide
- Initiated
- January 14, 2022 · Voluntary: Firm initiated
- Classified
- February 14, 2022
- Reported
- February 23, 2022
- Ended
- July 31, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Moxifloxacin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.